Numab
Wadenswil · Founded 2011
About Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $187.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2025)
- Website: numab.com
- Phone: 41445330471
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/numab-699 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.